The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 ,tg of dexamethasone/day to 150 g male rats. Marked dosedependent effects on body weight and nitrogen retention were produced, with the highest IGF-I dose, 695 ,tg/day, giving a 6 g increase in body weight over 7 days, compared with a 19 g loss in the dexamethasone-only group and an 18 g gain in pair-fed controls. Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I. The response with LR3IGF-I was particularly striking because this peptide binds 3-fold less well than IGF-I to the type 1 IGF receptor. The increased potencies of the IGF-I variants may relate to the substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3, produced by the combined treatment of dexamethasone with IGF-I or the variants. These binding proteins would be expected to decrease the transfer of IGF-I, but not that of the variants, from blood to tissue sites of action. Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes. Thus 3MH excretion was decreased at the highest IGF-I dose from 83.5 + 4.2 (s.E.M.) ,smol/kg per 7 days to 65.1 + 2.2, compared with 54.9 + 1.2 in the pair-fed controls. Part of this response in 3MH excretion may have reflected a decrease in gut protein breakdown, because IGF-I and especially the IGF analogues increased the gut weight by up to 45 %. Notwithstanding the effects on protein synthesis and breakdown, the fractional carcass weights remained low in the IGF-treated groups, although the increase in total carcass weight reflected nitrogen rather than fat gain. The dexamethasone-induced changes in liver, spleen and heart weight were restored towards normal by the IGF treatment. The experiment demonstrates the potential of IGF-I treatment of catabolic states and especially the value of modified forms of growth factors that bind weakly to IGF-binding proteins.
INTRODUCTION
Circulating levels of glucocorticoids are elevated as part of the acute or chronic response to infection, physical stress and other traumatic conditions. These changes, as well as increases produced by the exogenous administration of natural or synthetic glucocorticoids such as-dexamethasone, lead to atrophy of the musculature as a consequence of decreased protein synthesis and increased protein breakdown (Goldberg, 1969; Tomas et al., 1979 Tomas et al., , 1984a Odedra & Millward, 1982) . The concentration of insulin-like growth factor-I (IGF-I) in blood is decreased during polytrauma or after glucocorticoid administration (Coates et al., 1981; Frayn et al., 1984; Clemmons et al., 1985; Unterman & Phillips, 1985; Mosier et al., 1987) . This observation, taken together with experiments demonstrating that IGF-I stimulates protein synthesis and inhibits protein breakdown in cultured muscle cells (Ballard et al., 1986) , suggest that the administration of IGF-I to glucocorticoid-treated rats may partially reverse the catabolic state, through effects on muscle protein metabolism. Preliminary reports of improved nitrogen balance following IGF-I treatment of rats by Fagin et al. (1989 by Fagin et al. ( , 1990 ) support this inference.
In the present investigation we have measured the effects of IGF-I on nitrogen balance and muscle protein metabolism in rats given catabolic doses ofdexamethasone. Parallel experiments have been carried out with the truncated variant, des(l-3)IGF-I, and with LR3IGF-I (an extended, modified, form of IGF-I), because these analogues bind weakly to IGF-binding proteins and produce more potent anabolic responses than IGF-I does in cultured cells (Walton et al., 1990) .
MATERIALS AND METHODS

Growth factors
Recombinant human IGF-I and recombinant human des(l-3)IGF-I were supplied by Genentech Inc., South San Francisco, CA, U.S.A. Recombinant human LR3IGF-I was supplied by GroPep Pty. Ltd., Adelaide, S.A. 5000, Australia. This growth factor has arginine replacing glutamate at position 3 of human IGF-I and the N-terminal extension Met-Phe-ProAla-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn. The growth factors were dissolved in 0.1 M-acetic acid and administered to animals via Alzet model 2001 osmotic pumps that delivered 0.92,1l/h (Alza, Palo Alto, CA, U.S.A.). The concentrations used were 31.5, 12.6 or 5.0 mg/ml for IGF-I, and 12.6, 5.0 or 2.0 mg/ml for des(l-3)IGF-I and LR3IGF-I.
Animals
Male Hooded Wistar rats were bred in the CSIRO Division of Human Nutrition. From approx. 100 g body wt. they were maintained in Techniplast metabolism cages at 25°C with lighting controlled over a 12 h-light/ 12 h-dark cycle. The animals had continuous access to water and a high-carbohydrate diet containing 180 g of casein plus 2.5 g of methionine per kg as the nitrogen source (Tomas et al., 1984b The gut from stomach to caecum was also removed immediately, transferred to an ice/water mixture, and the combined weight was measured after removal of gut contents. Subsequently the pelt was stripped off, the remaining viscera were removed, the feet, tail and head were discarded and the carcass was frozen for subsequenlt water, nitrogen and fat measurements. The experiment was conducted in three parts. Sections 1 and 2 contained two animals in each control and treatment group, except that there were no pair-fed control animals. Section 3 of the experiment also contained two animals in each group, bringing the total number to six per group. In addition a second control group of six animals was included. These were pair-fed on the average food intake of the four animals in the dexamethasone-only group in sections 1 and 2 of the experiment. For this purpose the daily food intake was calculated on the basis of the body weight at the beginning of each 24 h period. The experimental protocol was approved by the Divisional Animal Care and Ethics Committee following the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Analytical methods
Methods for the measurement of nitrogen in urine, faeces, food and carcass, the analysis of urine 3-methylhistidine (3MH) and creatinine, carcass fat, muscle protein synthesis, IGF-I in acid-chromatographed portions of plasma and IGF-binding proteins have been described by Tomas et al. (1991b) . Plasma IGF-I was measured by a radioimmunoassay that utilized a monoclonal antibody kindly provided by Dr. R. Baxter, University of Sydney, Sydney, N.S.W., Australia, as well as with the polyclonal antiserum adopted for the study reported by Tomas et al. (199lb) . The monoclonal-antibody assay was identical with the polyclonal method, except for the use of sheep anti-mouse Ig (Silenus Laboratories, Hawthorn, Vic., Australia) as the second antibody. The monoclonal assay was included as it detects endogenous rat IGF-I only weakly. Thus rat IGF-I purified to homogeneity by the method described for bovine and ovine IGF-I (Francis et al., 1988 (Francis et al., , 1989 cross-reacted only 2.5 % relative to human IGF-I. The equivalent value with the polyclonal antiserum was 45%. Des(l-3)IGF-I and LR3IGF-I cross-reacted respectively 70% and 10% relative to human IGF-I with the polyclonal antiserum and 100 % and 2.9 % with the monoclonal antiserum.
Statistics
Values are presented as means + S.E.M. Between-treatment significance was assessed initially by two-way analysis of variance, partitioning variance due to sections and treatments. Where significance (P < 0.05) was achieved, the treatment means have been compared to the dexamethasone-only group by Student's t test using the pooled estimate of the standard error. Doseresponse curves have been compared by regression analysis. The dexamethasone-treated control group (dexamethasone-only) was excluded because log dose was used. The slopes and intercepts (at a dose of 165 ,ug/day) were compared by using t tests with appropriate corrections for multiple comparisons.
RESULTS
The present study was designed to evaluate the relative abilities of IGF-I and IGF-I variants to restore body-weight gain in the presence of a catabolic dose of dexamethasone, and to investigate the respective roles of muscle protein synthesis and degradation in the process. To this end a preliminary experiment (results not shown) established that dexamethasone doses between 10 and 40 ,ug/day given to 150 g male rats caused effects ranging from growth stasis to severe weight loss. A dose of 20 /tg/day induced an intermediate yet progressive weight loss of 20-25 g over 7 days, with the animals showing no apparent distress.
In the main investigation, IGF-I was administered at three doses, 695, 278 and 111 tg/day. The amounts of the two variants were set 2.5-fold lower, in recognition of the greater potencies of each in cultured cells (Walton et al., 1990) and, in the case of des(1-3)IGF-I, in nitrogen-restricted (Tomas et al., 1991a) and diabetic rats (Tomas etal., 1991b) . The daily body-weight changes over the 7-day period as well as for 3 pretreatment days are shown in Fig weights of untreated normal rats increased from an average of 152 g at the time the pumps were inserted to 197 g after 7 days, whereas the dexamethasone-treated control group (dexamethasone-only) lost an average of 19 g over the same period. Those control animals pair-fed on the intake of the dexamethasone-only group maintained their pretreatment weight over the first 4 days, when food intake was low (see below), and then gained weight to achieve a net average gain of 18 g. The animals treated with 695,ug of IGF-I/day plus dexamethasone gained 6 g over the 7-day period, thus restoring 25 of the 37 g difference between the dexamethasone-only and pair-fed control groups.
Nitrogen-balance results from the same four groups described in Fig. 1 are displayed in Fig. 2 . Before nitrogen analysis the urine and faeces were pooled over the 3 pretreatment days, as
Vol. 282 well as on days 1-3, 4-5 and 6-7. Before the treatment began, the nitrogen intakes (Fig. 2a) , excretions ( Fig. 2b) and retentions ( Fig. 2c) were similar between the groups. Nitrogen intake was subsequently decreased in the animals treated with dexamethasone only and gradually increased through the 7 days. No significant differences in intake between the dexamethasoneonly, pair-fed or dexamethasone-IGF-I groups were found, although the average intake in those animals treated with 695 ,ug of IGF-I/day was higher than the vehicle group unless nitrogen intake was expressed per kg body wt. rather than per animal. Nitrogen excretion (Fig. 2b) was decreased in the pair-fed animals relative to those fed ad libitum and was markedly increased (P < 0.001) on all three occasions by dexamethasone above the pair-fed group. Animals treated with 695 ,ug of IGF-I/day also excreted more nitrogen than the pair-fed controls, but the increases were less than in the dexamethasone-only group.
The amount of nitrogen retained was decreased in the pair-fed group below that found for the control animals fed ad libitum (Fig. 2c) and even further to a slightly negative balance in the dexamethasone-only group. At each pooled collection period the animals treated with 695 ,ug of IGF-I/day retained an amount of nitrogen which was below that of the pair-fed group, but significantly more (P < 0.01) on days 1-3 and days 6-7 than that found for the dexamethasone-only group.
The data for the three doses of the three IGF-I peptides are given below in the format of dose-response curves for the complete 7-day treatment period. The changes in body weight in the dexamethasone-only (-19.0+ 3.0 g) and low IGF-I dose (-21.2 + 2.5 g) groups were similar, but were increased significantly to -7.5 + 3.2 g (P < 0.05) with 278 ,g of IGF-I/day and to +6.2+0.6 g (P < 0.001) with 695 ,ug of IGF-I/day (Fig. 3) . Des(l-3)IGF-I and LR3IGF-I produced similar doseresponse curves that were displaced to the left of the IGF-I curve (Fig. 3) , with 111 ,ug doses of des(1-3)IGF-I or LR3IGF-I/day showing essentially the same effect as 278 ,g of IGF-I/day. Statistical comparisons between the three log/linear doseresponse regressions indicated that IGF-I was significantly less potent (P < 0.01) than the two variants.
Nitrogen retention expressed as the cumulative retention over the 7-day period (Fig. 4) gave a similar pattern to that obtained 1.22 ± 0.06t 6.13 ± 0.33t 10.24 ± 0.62 278 fg/day measured for the pair-fed control group. However, this 7-day total masked a progressive decline from a partial response early in the treatment period to a complete restoration of the average daily control rate during the last 2 treatment days (Fig. 6) Unlike the quantification of muscle protein breakdown, muscle protein synthesis could only be measured as the animals were killed. The synthesis rate, expressed as the percentage of the protein mass synthesized per day (Ks, %/day), was decreased in the dexamethasone-only group to 44 % of the value obtained in the pair-fed control animals (Table 1 ). This fall in K, was significantly less (P < 0.05) in the group receiving dexamethasone plus 695 ,ug of IGF-I/day, and to an even greater extent (P < 0.01) with dexamethasone plus 278 ,ug of des(1-3)IGF-I or LR3IGF-I/day. However, even the highest K, obtained was only 60 % of that measured in pair-fed controls.
The RNA content of muscle from the dexamethasoneonly group was 600/ of that from the pair-fed controls even though protein content remained unaffected by treatment (203.6 + 2.0 mg/g ;resultsnotshown).ThisdecreasedRNAcontent was only marginally increased even at the highest doses of IGF-I or IGF variants (Table 1) . Accordingly, muscle protein synthesis expressed as g of protein synthesized/day per g of RNA was decreased to a relatively smaller extent after dexamethasone treatment. This rate' was partially restored by the medium and high doses of des(l-3)IGF-I as well as by the high dose of LR3IGF-I (Table 1) .
The fractional weights (g/kg body wt.) of several organs were altered by dexamethasone ( Table 2 ). The carcass weight was decreased from 452 + 6 g/kg in the pair-fed controls to 399 + 6 g/kg in the dexamethasone-only group. No dose of IGF produced any significant restoration of the fractional carcass weight. A similar situation occurred with the thymus, which was decreased by 800% in weight by dexamethasone. The spleen weight was also decreased markedly after dexamethasone treatment, but with this organ a dose-dependent increase was produced by each IGF peptide (Table 2) . Very substantial increases in the total gut weight occurred in animals given IGF-I, des(l-3)IGF-I and especially LR3IGF-I. Liver and kidney weights were increased by dexamethasone. The liver weights were decreased somewhat in a dose-dependent manner by each IGF peptide, whereas kidney weights were further increased, especially at the lowest doses of IGF-I and des(l-3)IGF-I. Higher deses of the IGF peptides appeared to decrease kidney weights (Table 2) . Of the other tissues measured, no effects-of any IGF peptide were found with the pelt, lungs or adrenals. The heart weight was increased by dexamethasone and partly restored Plasma was obtained from blood collected when the animals were killed on day 7 of the experiment. After molecular-sieve chromatography under acid conditions to remove binding proteins, the IGF was measured by using either a polyclonal or a monoclonal antihuman IGF-I antibody with human IGF-I as reference. of each IGF peptide produced highly significant (P < 0.01 or P < 0.00 1) increases in carcass water, protein and total weight. In contrast with these responses, no significant effects of the IGF peptides were observed with fat, which remained at approx. 4 g per carcass even under those conditions where the total carcass weight was 20% higher. The circulating IGF-I levels achieved on the last treatment day are shown in Table 4 . IGF-I measured with the polyclonal antibody was decreased by dexamethasone and increased above this value 2.4-, 3.0-and 4.1-fold by the increasing doses of exogenous IGF-I. Small increases occurred with des(l-3)IGF-I and essentially none with LR3IGF-I, consistent with the immunological cross-reactivities of these variants in the polyclonal assay. Similar results were found with the monoclonal-antibody assay when allowances were made for the higher des(l-3)IGF-I crossreactivity and the very weak cross-reactivity with rat IGF-I (Baxter et al., 1982) .
The circulating IGF-binding proteins were assessed by the ligand-blot procedure (Hossenlopp et al., 1986) . At the autoradiograph exposure used, binding proteins were only barely detected in controls fed ad libitum, pair-fed and dexamethasoneonly groups (Fig. 7) . However, the administration of all three IGF peptides led to substantial induction of the IGF-bindingprotein (IGFBP)-3 triplet, with the effects somewhat less with LR3IGF-I. DISCUSSION +LR3IGF-I, 446+40 198 + 38 Subcutaneous administration of IGF-I to normal (Hizuka et 278 ,ug/day al., 1986; Fagin et al., 1990) , hypophysectomized (Schoenle et al., 1985) , nitrogen-restricted (Tomas et al., 1991a) , diabetic (Scheiwiller et al., 1986; Tomas et al., 1991b) or partially gutLane resected (Lemmey et al., 1991) (1989, 1990) and further establishing the generality of IGF-I as a growth promotant.
-
The activities of des(l-3)IGF-I and LR3IGF-I are striking. Both variants are approx. 2.5-fold more potent than IGF-I at improving weight gain and nitrogen retention when the com-21 parisons are made at the midpoints of the dose-response plots (Figs. 3 and 4) and somewhat more active at lower doses. The (Forbes et al., 1988; Walton et al., 1990) , a property that analysed by the ligand-blotting technique, using 125I-labelled IGF-I may increase their delivery from the blood to tissue sites of as the probe. The molecular masses of protein standards are shown.
action. Certainly the pharmacokinetics of des(l-3)IGF-I indicate The lanes represent 5 ,ul of plasma obtained from the following a faster removal rate of this variant from the blood (Ballard et treatment groups: 1, controls fed ad libitum; 2, dexamethasone only; al., 1991). Notwithstanding its very low binding affinities for 3, pair-fed controls; 4, des(I-3)IGF-I at 44 ,ug/day; 5, LR3IGF-I at several IGF-binding proteins, the high potency of LR3IGF-I is 44 jug/day; 6, IGF-I at 111 ,ug/day; 7, des(I-3)IGF-I at 111 ,ug/day; . . 8, LR3IGF-I at 111 g/day; 9, IGF-I at 278 pg/day; 10, surprising, because this variant has a 3-fold lower affinity than des(I-3)IGF-I at 278,fg/day; 11, LR3IGF-I at 278,fg/day; 12, IGF-I or des(I-3)IGF-I for the type 1 IGF receptor (Walton et IGF-I at 695 ,fg/day. al., 1990) . We presume that the low receptor affinity of LR3IGF-I must be counteracted by an even more rapid transfer from blood to tissues or higher local free concentrations than found to normal by the highest doses of IGF-I, des(l-3)IGF-I or for des(I-3)IGF-I. It is important to note that the higher LR3IGF-I (results not shown (Zapf et al., 1989;  hydrate) from the values obtained in the pair-fed animals. Tomas et al., 1991a,b (Tables 2 and 3 ). The highest doses of IGF-I, des(I-3)IGF-I and LR3IGF-I led to 10-18 % increases in carcass protein above the dexamethasone-only group. These results are consistent with the decreased rate of muscle protein breakdown as measured by 3MH excretion throughout the IGF treatment period as well as the higher rates of muscle protein synthesis on day 7. We should also consider that the fall in 3MH excretion produced by the IGF peptides in part may reflect a decrease in the amount of this amino acid released from non-skeletal-muscle sources of actin or myosin. In this context it has been argued that intestinal smooth muscle contributes significantly to urinary 3MH in the rat (Millward & Bates, 1983) . However, a fall in gut-derived 3MH in IGF-treated rats will be compensated, at least in part, by the concomitant increase in gut mass.
The effects of IGF peptides on 3MH excretion differ substantially between dexamethasone-treated animals and diabetic animals. Since 3MH excretion is not decreased at all by IGF treatment of diabetic rats (Tomas et al., 1991b) , notwithstanding a powerful growth response. In contrast with IGF, insulin treatment of the diabetic animals decreased 3MH excretion to normal. It is possible that insulin might have contributed to the fall in 3MH excretion in dexamethasone-treated animals between days 1-3 and days 6-7 (Fig. 6 ), because insulin levels are known to increase after glucocorticoid administration (Tomas, 1982) . We note, however, that none of the IGF treatments affected plasma glucose or glucose excretion in these mildly hyperglycaemic dexamethasone-treated rats (results not shown). The effects on protein synthesis also differ from those reported for diabetic rats (Tomas et al., 1991b) , where there were no changes in translational efficiency as measured by synthesis per unit of RNA. In diabetic animals, IGF treatment increased protein synthesis by restoring the RNA content to normal. Dexamethasone, on the other hand, decreased the capacity for protein synthesis as measured by RNA content, as well as the translational efficiency (Table 1) . Both were partially increased by the higher doses of IGF peptides.
In a number of experimental conditions the administration of IGF-I leads to increases in spleen and thymus weights (Guler et al., 1988; Binz et al., 1990; Lemmey et al., 1991) . A similar effect on the spleen occurred here, since the decrease in spleen weight in the dexamethasone-treated rats was partly prevented by IGF treatment (Table 2) . However, the thymus weight was not increased. We therefore infer that the immunosuppressive effects of dexamethasone that lead to thymus atrophy cannot be prevented by IGF-I.
Although exogenous glucocorticoids may not fully mimic the response to trauma or stress, the results presented here certainly suggest that the administration of IGF-I to cases of polytrauma will lead to an amelioration of the attendant catabolism and, hence, improved recovery. Moreover, IGF variants that bind poorly to the circulating binding proteins are likely to be significantly more potent than IGF-I.
